Abdel-Aziz Heba, Kelber Olaf, Lorkowski Gerhard, Storr Martin
Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany.
GL Pharma Consulting Research & Development, Gauting, Germany.
Planta Med. 2017 Oct;83(14-15):1130-1140. doi: 10.1055/s-0043-116852. Epub 2017 Aug 31.
Herbal combination preparations are widely used in traditional herbal medicine and are even established as modern evidence-based herbal medicinal products. The rationale behind such combinations is often questioned and assessing the contribution of each of the combination partners to overall activity is challenging. STW 5 (Iberogast) is such a combination with confirmed clinical efficacy in functional gastrointestinal disorders. It consists of nine plant extracts responsible for its multitarget function in these multifactorial diseases with their heterogeneous and overlapping pathomechanisms. This makes the combination an ideal candidate for the use of the newly described method of stepwise cluster analysis, a standardized procedure to transfer heterogeneous pharmacological data, from different models, into effect size categories. This allows for a stepwise cluster formation starting from the level of single tests up to the level of different pathomechanisms involved in the development of a certain disease, in this case functional dyspepsia subtypes and irritable bowel syndrome. In the current article, an overview on the pharmacological data on STW 5 and its single components is provided. The data are further analyzed using stepwise cluster formation, resulting in a summary of the different modes of action of STW 5 along with an evaluation of the contribution of the single constituents to the overall multitarget effects of the herbal combination preparation.
草药复方制剂在传统草药医学中广泛应用,甚至已成为现代循证草药产品。此类复方制剂背后的原理常受到质疑,评估复方中各成分对整体活性的贡献具有挑战性。STW 5(伊贝戈斯特)就是这样一种在功能性胃肠疾病中具有确切临床疗效的复方制剂。它由九种植物提取物组成,在这些具有异质性和重叠发病机制的多因素疾病中发挥多靶点作用。这使得该复方制剂成为使用新描述的逐步聚类分析方法的理想候选对象,逐步聚类分析是一种将来自不同模型的异质药理学数据转化为效应量类别的标准化程序。这允许从单个试验水平开始逐步形成聚类,直至涉及某种疾病(在本例中为功能性消化不良亚型和肠易激综合征)发生发展的不同发病机制水平。在本文中,提供了关于STW 5及其单一成分的药理学数据概述。使用逐步聚类形成对数据进行进一步分析,得出STW 5不同作用模式的总结以及对单一成分对草药复方制剂整体多靶点效应贡献的评估。